REVITALIZE (Ovarian Cancer)

REVITALIZE (Ovarian Cancer)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to test a telehealth intervention that is designed to help women who are suffering from fatigue while taking parp inhibitors for their ovarian cancer. We want to know how well it works compared to current, standard clinical methods.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with ovarian, fallopian tube, or primary peritoneal cancer
  • Have completed surgery and chemotherapy
  • Have been taking a parp inhibitor for at least 2 months
  • English speaking
  • Have a high level of fatigue
For more information, contact the study team at amelia.lorenzo@duke.edu.

Age Range

18-110

Sex/Genders

Female (cisgender)
Transgender male
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 groups:
  • The telehealth intervention group; OR
  • The standard-of-care group
If you are assigned to the telehealth group, you will participate in a series of telehealth sessions designed to reduce the effects of fatigue. There will be 10 sessions over the course of 6 months. If you are assigned to the standard-of-care group, you will receive informational print outs about managing fatigue and other side effects of parp inhibitors.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

Randomized trial of REVITALIZE: A telehealth intervention to reduce
fatigue interference among adults with advanced ovarian cancer on PARP inhibitors

Principal Investigator

Laura
Havrilesky

Protocol Number

PRO00116245

Phase

III

Enrollment Status

Pending Open to Enrollment